Mersana Therapeutics Inc MRSN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRSN is a good fit for your portfolio.
News
-
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
-
Mersana Therapeutics to Present at Upcoming Investor Conferences
-
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
-
Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference
-
Mersana Therapeutics Shares Rise 8% After FDA Lifts Clinical Hold for Cancer Treatment
-
Mersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I Trial
-
Mersana Therapeutics's stock craters after FDA halts trials of ovarian cancer treatment after patient deaths
Trading Information
- Previous Close Price
- $2.85
- Day Range
- $2.76–2.96
- 52-Week Range
- $0.80–9.62
- Bid/Ask
- $2.86 / $2.97
- Market Cap
- $356.63 Mil
- Volume/Avg
- 858,610 / 2.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.07
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 123
- Website
- https://www.mersana.com
Comparables
Valuation
|
Metric
|
MRSN
|
CLDX
|
IGMS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 9.42 | 4.73 | 2.21 |
Price/Sales | 9.07 | 255.51 | 187.88 |
Price/Cash Flow | — | — | — |
Price/Earnings
MRSN
CLDX
IGMS
Financial Strength
|
Metric
|
MRSN
|
CLDX
|
IGMS
|
|---|---|---|---|
Quick Ratio | 3.29 | 13.69 | 7.95 |
Current Ratio | 3.36 | 13.87 | 8.18 |
Interest Coverage | −44.11 | — | — |
Quick Ratio
MRSN
CLDX
IGMS
Profitability
|
Metric
|
MRSN
|
CLDX
|
IGMS
|
|---|---|---|---|
Return on Assets (Normalized) | −49.57% | −30.49% | −44.52% |
Return on Equity (Normalized) | −211.52% | −33.19% | −84.37% |
Return on Invested Capital (Normalized) | −146.81% | −32.85% | −77.23% |
Return on Assets
MRSN
CLDX
IGMS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sxmsmtbxf | Yrmj | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nyhsynz | Ckpyp | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mbckbgvr | Ggkmww | $97.8 Bil | |
MRNA
| Moderna Inc | Xqqfskzmf | Kvy | $41.3 Bil | |
ARGX
| argenx SE ADR | Gfzqlzxwf | Bqvm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Krpmfhncz | Dnpjg | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mhkzfvb | Dktdgt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rwmkwjw | Shyzwzl | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xxygjgdx | Kqxvrvg | $12.5 Bil | |
INCY
| Incyte Corp | Dbnfymtdv | Srzxl | $11.6 Bil |